Whilst inhibition of the proteasome leads to an accumulation of HIF-1α, the HIF-1α that accumulates is transcriptionally inactive.99 A proteasome inhibitor, bortezomib (Fig. 3l), has been FDA approved for treatment of numerous cancers. The gene discussed is HIF1A; the disease is cancer.